GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1×1 meetings at the following investor conferences:
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the…
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE:…
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…
SAN DIEGO, June 21, 2024 /PRNewswire/ -- Cryo Sculpting Lab (CSL), a pioneer in non-invasive…
FREDERICK, Md., June 21, 2024 /PRNewswire/ -- Service Coordination Inc. (SCI), a leading provider of…
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug…